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A ge-related macular degeneration (AMD) is the leading cause of irreversible blindness among the elderly worldwide. 1, 2 Abnormal complement pathway regulation and retinal pigment epithelium cells (RPE) dysfunction have both been implicated in the early pathogenesis of the disease, [3] [4] [5] and specifically in the formation of drusen. 6, 7 Approximately 70% of AMD patients are homo-or heterozygous for a specific polymorphism of the gene encoding for the endogenous complement pathway regulator Factor H (CFH), with additional contributions of polymorphisms in the genes encoding for Factors B, C2, and C3. [8] [9] [10] [11] The single nucleotide change (1277 TC, rs1061170) in the CFH gene results in the substitution of histidine for tyrosine at codon 402 of the CFH protein, which subsequently leads to a more than 2-fold increase in risk of AMD in CT heterozygotes (carriers of one single copy of the C allele) and a 3-to 6-fold increase in individuals homozygous for the CC genotype compared with the TT genotype. [12] [13] [14] [15] [16] This results in a prolonged state of complement activation, which results in the assembly of the C5b-C9 membrane attack complex and cell lysis, concurrently with liberation of C3a and C5a, two small pro-inflammatory peptide fragments. Most of the complement pathway proteins are present in Bruch's membrane, drusen, and RPE of AMD patients. [17] [18] [19] [20] [21] [22] Although the involvement of the complement pathway in the pathogenesis of AMD has unambiguously been established, it is not exactly known how a chronically overactive complement system triggers the development of AMD. 23 Nonlysosomal proteolysis is essential for cell survival. In eukaryotic cells, the ubiquitin-proteasome pathway (UPP) is the major nonlysosomal proteolytic pathway. 24 Most cytoplasmic and nuclear proteins become ubiquitinated in order to target these proteins for degradation. Once ubiquitinated, these Copyright 2013 The Association for Research in Vision and Ophthalmology, Inc. www.iovs.org j ISSN: 1552-5783 proteins are recognized by the 19S regulatory particle that together with the 20S catalytic core forms the 26S proteasome. Upon de-ubiquitination and unfolding, the protein enters the cylinder-shaped 20S core particle, which is formed by stacked catalytic subunits that possess hydrolytic activity for the cleavage of the carboxyl end of proteins. There are three catalytic subunits in the standard proteasome: b1 for acidic amino acids, b2 for basic amino acids, and b5 for hydrophobic amino acids. The immunoproteasome is formed upon replacement of the constitutive subunits in the standard proteasome by the inducible subunits, the so-called b1i, b2i, and b5i. 25, 26 The immunoproteasome is involved in specific, biological processes including generation of immunogenic peptides for antigen presentation, 27, 28 degradation of oxidized proteins, 29 cell signaling, 6, 30, 31 neuronal maintenance, and synaptic vesicle formation. 32 Therefore, the ratio between proteasomes containing the standard catalytical subunits (b1, b2, and b5) or the corresponding inducible subunits (b1i, b2i, and b5i) can change during inflammation and other stressful situations.
Retinal pigment epithelial cells (RPE) have an active UPP, but relatively limited levels of endogenous ubiquitin, which render these cells more vulnerable to cellular stressors. 33 Abnormalities in the UPP have been implied in the pathogenesis of many ageing diseases, such as Alzheimer's disease, 34 Parkinson's disease, 35 and cataract. [36] [37] [38] The aim of the present study was to investigate the involvement of the proteasome in AMD in relation to complement overactivation. The chymotrypsin-like activity (b5) of the proteasome appears to be the rate-limiting activity of the proteasome, 39, 40 and it has been shown that ageing affects its functioning in the retina. 41 For this reason, b5 proteasome subunit and its immunoproteasome counterpart b5i were characterized both in cell cultures of complement-activated human retinal pigment epithelial cells (HRPE) and in a mouse model for age-related atrophic degeneration of the RPE.
MATERIALS AND METHODS

Immunohistochemistry
To characterize b5 and b5i proteasome subunit expression in the RPE of AMD tissue, whole retinal sections (2-lm thick) of 500 day-old monocyte chemoattractant protein-1-deficient CCL2 À/À mice (n ¼ 3) and wild-type mice (n ¼ 3) were stained with mouse antibodies against the b5 and b5i subunits of the 20S proteasome and the b5i subunit of the 20S proteasome (Abcam, Cambridge, UK) and visualized by immunofluorescence. CCL2 À/À mice were obtained from The Jackson Laboratory (B6.129S4-Ccl2 tm1Rol /J, stock no. 004434; Bar Harbor, ME), and these do not contain the rd8 mutation. 42 All the animals were treated according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Briefly, sections were fixed in 2% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA), equilibrated, and rinsed in 1% PBS four times for 5 minutes, blocked in 10% normal goat serum (Invitrogen, Breda, The Netherlands) for 30 minutes, again rinsed in 1% PBS three times for 5 minutes. Then, sections were incubated in the presence of the primary antibodies for 1 hour at room temperature in a dilution of 1:500 followed by rinsing in PBS and incubation with appropriate secondary goat anti-mouse antibodies, conjugated with Cy3 in a dilution of 1:500 (Jackson, Suffolk, UK), and rinsed in PBS. Sudan Black B staining was performed by incubating sections in a freshly prepared solution of 1% Sudan Black B (Fisher Biotech, Pittsburgh, PA) diluted in 70% ethanol for 10 minutes, followed by brief rinsing in 70% ethanol, and rinsing in distilled water. As controls, whole retinal sections with no antibody treatment nor Sudan Black B staining, as well as whole retinal sections with only Sudan Black B staining were used. Sections were counterstained with 4 0 -6-diamidino-2phenylindole (DAPI; Vector, Burlingame, CA).
Culture, Maintenance, and Treatment of HRPE Cells
Donor eyes were obtained from the Euro Cornea Bank (Beverwijk, The Netherlands) after removal of corneal buttons for transplantation. Donor eyes were acquired with consent of the donor or donor family to be used for medical research in accordance with the principles outlined in the Declaration of Helsinki. Characterization of the donors is summarized in Table 1 .
For isolation of the HRPE, donor eyes with a post mortem time of less than 15 hours (average postmortem time, 12 hours) were obtained from 17 donors between 13 and 76 years of age. The RPE was isolated from the sclera together with the choroid after dissection of the anterior and posterior segment of the eye. The tissue was subsequently incubated for 1 hour at 378C in a 6-well plate with 2 mL digestion medium (TrypLE Express; Invitrogen). The RPE and choroid were separated after adding 2.5 mL of F99 medium to the digestion mixture and transferring the tissue to an empty well containing 2.5 mL of F99 medium. Medium containing the RPE cells was then transferred to a cell strainer with 70-lm meshes and centrifuged for 10 minutes (400g, 1000 rpm). Supernatant was collected and diluted in 12 mL F99 medium. A suspension of cells in 1 mL F99 medium was transferred to a gelatin-coated 6-well plate.
Growth of cells was monitored and medium was changed every 2 days. After 8 days, the confluent cells were washed with PBS and 0.5 mL TrypLE Express, and 1 mL F99 medium was added. The contents of three wells were then transferred to a fibronectin-coated 75-cm 2 flask, which renders four flasks for passage 1 for each pair of eyes. The medium was replaced by human endothelial serum-free medium upon confluence. In passages 2 through 4, cells were used for experiments upon attaining 100% confluence. The cultured RPE cells exhibited an epithelial cell shape and contained pigment granules in the perinuclear region. The expression of RPE-specific marker genes CRALBP, RPE65, and FGFR2 as determined by RT-PCR analysis indicated the identity and high differentiation state of the cells as well. When cells were cultured on transwell inserts, a transepithelial resistance was obtained between 36 and 64 Xcm 2 . Proper polarization of HRPE cells was verified by a positive staining of ZO-1 and occludin protein ( Fig. 1 ).
To investigate the effect of complement factors, inflammation, and oxidative stress, RPE cells were stimulated with C3a (50 ng/mL or 100 ng/ml; R&D Systems, Minneapolis, MN), C5a (50 ng/ml; R&D Systems), IFN-c (50 U/mL; PBL Biomedical, Piscataway, NJ; and U-CyTech Biosciences, Utrecht, The Netherlands) in serum-free medium for 72 hours.
Genotyping
Ten donors were genotyped for the CFH Y402H polymorphism (1277 TC, rs1061170) in 2 ng genomic DNA extracted from RPE cells using a standard Taqman assay ( Table 2) . 43 Genotype assessment for CFH Y402H polymorphism in the 10 donors used for protein analysis showed six C allele carriers, of which three had the CC genotype, three the CT genotype, and four the TT genotype ( Table 2 ).
Preparation of Photoreceptor Rod Outer Segments
Photoreceptor outer segments (POS) were added to cultured HRPE cells to mimic the situation in vivo where RPE continually phagocytoses POS. Photoreceptor outer segments were isolated from bovine eyes obtained freshly from the slaughterhouse. 44, 45 Photoreceptor outer segments were stored suspended in a solution of 10 mM sodium phosphate (pH 7.2), 0.1 M sodium chloride, and 2.5% sucrose at À808C. Before use, POS were thawed and labeled by addition of 20% volume of 1 mg/mL FITC (Molecular Probes, Invitrogen, Carlsbad, CA) in 0.1 M sodium bicarbonate (pH 9.0), for 1 hour at room temperature in the dark. Photoreceptor outer segments were then washed and resuspended in cell culture media.
Proteasome Activity Measurements by Flow Cytometry of HRPE Cells
Proteasome activity was determined using the probe BodipyFl-Ahx 3 L 3 VS (provided by Hermen Overkleeft), 46 which has a similar affinity for all catalytically active subunits of proteasomes in living cells. This probe has a green emission spectrum (1 ex ¼ 480 nm, 1 em ¼ 530 nm) and can be used for both flow cytometry (FACS) experiments and confocal laser scanning microscopy (CLSM). 46, 47 The following cell culture samples were tested for proteasome activity by means of FACS: unstimulated HRPE, POS-fed RPE, C3a-stimulated HRPE, C3a-stimulated POS-fed HRPE, IFN-c-stimulated HRPE, and HRPE with and without C3a stimulation treated for 1 hour with 500 nM of the proteasome inhibitor epoxomicin (Ep; Sigma-Aldrich, St. Louis, MO). In total, seven human donors were used and divided in a ''young age'' group (n ¼ 3; 13, 23, and 37 years old) and an ''old age'' group (n ¼ 4; 47, 55, 57, and 65 years old).
Flow cytometry experiments were performed on a FACS LSRII (Becton Dickinson, Breda, The Netherlands). For uptake experiments, untreated cells, and C3a-treated cells were incubated with 500 nM BodipyFl-Ahx 3 L 3 VS for 2 hours. The treated cells were stimulated with 50 ng/mL recombinant human C3a. Cells were washed, trypsinized, and resuspended in medium, and intracellular fluorescence was measured. As a negative control, cells were incubated with 500 nM Ep overnight. Unstained HRPE cells were used to normalize the signal. Two or three parallel wells were used for each experimental condition. Approximately 10,000 of unfixed RPE cells were used for the experiments and a live gate was used to exclude cell fragments, POS particles, and other unwanted debris. The background fluorescence of the system, as assayed without any cells, was subtracted. A logarithmic scale of relative fluorescent intensity was used and signal intensity was calculated by subtracting the geometric mean autofluorescence of control cells from the geometric mean fluorescence of cells incubated with BodipyFl-Ahx 3 L 3 VS.
Confocal Laser Scanning Microscopy
To visualize active proteasomes in HRPE cells using a TCS SP2 CLSM (Leica, Rijswijk, The Netherlands), the following cell culture samples were incubated with BodipyFl-Ahx 3 L 3 VS: unstimulated HRPE, C3a-stimulated HRPE, IFN-c-stimulated HRPE, and HRPE with and without C3a stimulation treated for 1 hour with Ep. Two samples of HRPE cells of two donors were studied. Untreated and C3a-treated cells were incubated for 2 hours with the probe and washed with medium before being imaged. Treated HRPE cells were stimulated with 50 ng/mL C3a. As a negative control, cells were incubated with 500 nM Ep overnight before incubation with the activity probe.
Protein Extraction and Western Blot Analysis
For Western blot analysis, protein lysates of 10 donors (three samples per experimental condition) were collected in 100 mL lysis buffer (1% Triton X-100, 50 mM HEPES, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM phenylmethanesulfonyl fluoride, 1X phosphatase inhibitors, and 1X Western blot analyses were performed as described previously. 48 Twenty micrograms of protein were separated on a 12.5% SDS-PAGE, transferred to polyvinylidene difluoride membranes and semiquantitatively analyzed. Membranes were incubated for 16 hours at 48C with a monoclonal antibody against the a7 and a2 subunit of the 20S proteasome and one of the following polyclonal antibodies: anti-b5 subunit of the 20S proteasome, anti-b5i subunit of the 20S proteasome, and anti-11S regulator subunit PA28a (Enzo Life Sciences, Zandhoven, Belgium). All primary antibodies were diluted 1:500 in 3% nonfat dry milk (Bio-Rad, Hercules, CA) in TBS/0.05% Tween-20. Infrared dye-conjugated goat anti-rabbit (for b5, b5i, and PA28a) and goat anti-mouse (for a7 and a2) secondary antibodies (LI-COR Biosciences, Lincoln, NE) were diluted 1:10,000. Immune reactions were quantified by densitometric analysis using Odyssey (LI-COR Biosciences). Anti-b-actin antibody was used to stain a reference sample to normalize sample reactions and allowed for comparison between blots. All Western blot experiments were performed at least twice.
Proteasome Activity Measurements in Cell Extracts
Retinal pigment epithelial cells from a young and old donor were harvested in TSDG buffer (10 mM Tris, pH 7.5, 25 mM KCl, 10 mM NaCl, 1.1 mM MgCl 2 , 0.1 mM EDTA, and 8% glycerol) and lysed by three freeze/thaw cycles in liquid Gene nomenclature, GenBank accession code, primer sequences, and predicted size and Tm of the amplified product.
FIGURE 2. (A)
Proteasome b5 subunit content is constant in CCL2 À/À mice. Whole retina sections from wild-type and CCL2 À/À mice were stained with antiproteasome b5 antibody and visualized by immunofluorescence microscopy (in pink). Proteasome b5 subunit was present in the nuclei and perinuclear region of the RPE of both wild-type and CCL-2 À/À mice. (B) Proteasome b5i subunit protein expression is upregulated in CCL2 À/À mice. Whole retina sections from wild-type and CCL2 À/À mice were stained with antiproteasome b5i antibody and visualized by immunofluorescence microscopy. Proteasome b5i subunit was not present in the RPE of wild-type mice. Immunoproteasome b5i subunit was upregulated in the nuclei and perinuclear regions of the RPE of CCL2 À/À mice.
nitrogen. After centrifugation (15 minutes, 21,000g), the protein concentration in the supernatant was determined by a Bradford protein assay (Serva, Heidelberg, Germany). Proteasomes were labeled in the lysate with 0.5 lM Bodipy-Ep probe for 1 hour at 378C. 49 Six times sample buffer (350 mM Tris/HCl, pH 6.8, 10% SDS, 30% glycerol, and 6% bmercaptoethanol) was added to 30 lg lysate. The samples were boiled for 3 minutes and loaded on a 12.5% SDS-PAGE gel. Afterwards, fluorescent imaging was performed on a Trio Thyphoon (GE Healthcare, Madison, WI) using the 580 bandpass (BP) 30 filter to detect the Bodipy-Ep probe directly in the gel. Subsequently, the gels were used for Western blot analysis to determine the proteasome levels using a2 subunit levels as a loading control, using the MCP236 antibody (Enzo Life Sciences). Antibody detection was performed using the Odyssey detection system (LI-COR Biosciences). 
RNA Isolation and mRNA Quantification
Statistical Analysis
Gene expression data showed a normal distribution. Differences in gene expression levels between groups were calculated by using single ANOVA with P < 0.05 indicating significant differences (two-tailed).
For proteasome activity in FACS assays, the total fluorescence intensities from two independent preparations in each group were calculated. Data are presented as mean 6 SEM with statistical differences between groups analyzed by standard two-tailed t-test using GraphPad Prism (version 5.00 for Windows, www.graphpad.com; GraphPad Software, San Diego, CA) and a P < 0.05 indicating statistically significant differences.
RESULTS
Increased b5i:b5 Ratio in RPE of CCL2 À/À Mice Immunofluorescence of proteasome subunits b5 and b5i in retinas of CCL2 À/À mice (n ¼ 3) and wild-type mice (n ¼ 3) showed the subunits to be localized in nuclei and perinuclear regions of RPE cells. Retinal pigment epithelium of agematched wild-type and CCL2 À/À mice showed similar levels of b5 staining ( Fig. 2A) . However, the RPE of CCL2 À/À mice also showed high levels of the b5i subunit, while no b5i subunit staining was observed in RPE of wild-type mice (Fig. 2B ). This translated in a higher b5i:b5 ratio in the RPE of CCL2 À/À mice. These results suggest that proteasome activity may be altered in age-related maculopathy.
Overall Activity of the RPE Proteasome Is Decreased Upon C3a Stimulation in HRPE Cells
Overall proteasome activity was visualized in RPE cells at 72 hours by CLSM imaging and subsequently quantified by FACS assays using the activity probe BodipyFl-Ahx 3 L 3 VS. Confocal scanning laser microscope images showed active proteasomes in nuclei and cytoplasm of HRPE cells. In comparison to untreated cells, HRPE cells treated for 72 hours with C3a showed decreased proteasome activity. Cells treated with the proteasome inhibitor, Ep, showed 80% inhibition of protea-some activity (n ¼ 7; P < 0.01; Fig. 3 ). C3a-treated HRPE cells of younger donors (13-37 years old, n ¼ 3) showed no differences in proteasome activity when compared with untreated HRPE (P > 0.05, Fig. 4A ), whereas C3a-treated HRPE cells of older donors (47-65 years old, n ¼ 4) showed a 37% decrease in proteasome activity when compared to agematched untreated HRPE cells (P < 0.05, Fig. 4B ). Treatment of HRPE cells with IFN-c caused a 76% increase in proteasome activity (n ¼ 7, P < 0.01). Photoreceptor outer segments-fed cells did not show altered proteasome activity (data not shown). Moreover, the CFH Y402H polymorphism did not affect proteasome activity in untreated and C3a-treated HRPE cells. Overall, these results suggest that complement factor C3a causes decreased proteasome activity in HRPE cells of older individuals.
Specific Proteasome Subunit Activities Are Not Affected by C3a in HRPE Cells
To further characterize whether decreased overall proteasome activity was due to changes in the activities of specific proteasome subunits, we used a Bodipy-Ep probe to label the individual catalytic proteasome subunit activities upon separation by SDS-PAGE (Fig. 5 ). Retinal pigment epithelial cells from young and old donors were used (ages 23 and 65 years old, respectively). As expected, IFN-c caused increased activity of immunoproteasomes as indicated by the increase in b2i (14.7fold higher on average in all donors), and b5:5i:1i levels in the young donor (2.7-fold higher when compared with control). However, treatment with either a high or low concentration of C3a did not induce any changes in b2, b2i, b1, and b5:5i:1i activity levels when compared with control HRPE cells. These results indicate that overall decreased proteasome activity upon C3a stimulation is not due to changes in the activity of specific proteasome subunit complexes, but rather affects proteasome activity posttranslationally.
Expression of Proteasome Is Not Affected by C3a Stimulation in HRPE Cells
To assess whether the observed decrease in proteasome activity upon C3a treatment was due to an alteration in expression of proteasome subunits, we measured total proteasome content ( Fig. 6) . Levels of the different proteasome subunits were evaluated using the a7 and a2 subunits of the 20S core. Densitometric analysis revealed no statistically significant differences in the content of a7 (n ¼ 6) and a2 (n ¼ 8) proteasome subunits after treatment with C3a, C5a, or IFN-c.
Immunoproteasome Expression Is Not Affected by Complement Over Activation in HRPE Cells
Untreated HRPE cells showed protein levels of both the constitutive subunit b5 and the inducible subunit b5i of the proteasome that were similar in C3a-stimulated HRPE cells (n ¼ 8, P > 0.05, Fig. 7) . In IFN-c-treated HRPE cells, the protein levels for the immuno-subunit b5i were on average 1.8-fold higher than in control HRPE (n ¼ 8, P < 0.05), whereas those of the constitutive b5 subunit were on average 0.8-fold lower than in untreated HRPE (n ¼ 8, P > 0.05). This translated in a statistically significant increased average b5i:b5 ratio of 2.3 for IFN-c-treated HRPE cells (n ¼ 8, P < 0.01). These results show that inflammatory mediators, but not complement activation, may explain the change in the conformation of the proteasome in RPE cells in mice, as the decreased proteasome overall activity found in the HRPE cells treated with C3a cannot be explained by changes in the content of b5 or b5i. No significant association was found between age, CFH Y402H polymorphism and change in proteasome protein content.
No Alterations in PA28 Levels Upon C3a Stimulation in HRPE Cells
As changes in proteasome activity can also be induced by the proteasome activator PA28, which can replace the 19S cap as an alternative proteasome activator binding to the 20S proteasome core, we determined the total content of the proteasome regulatory complexes by antibody reactions against the a-subunit of PA28, another proteasome regulatory complex.
We did not find any significant change in content of PA28a protein levels due to C3a treatment. A significant 4.6-fold increase was found in IFN-c-stimulated HRPE cells (n ¼ 5, P < 0.01, Fig. 8 ). These data suggest that decreased proteasome overall activity upon C3a stimulation is not due to altered PA28 levels, a mechanism by which IFN-c and other inflammatory mediators are known to upregulate the level of the immunoproteasome.
C3a Stimulation in HRPE Cells Does Not Change mRNA Expression of Proteasome-Related Genes
We assessed mRNA levels of proteasome-related genes, PSME1 (PA28), PSMB5 (b5 subunit), PSMA7 (a7 subunit), and PSMB8 (b5i subunit) in untreated HRPE cells and HRPE cells treated with C3a, IFN-c, and H 2 O 2 . Expression of the C5a receptors, human C5aR (hC5aR) and human C5L2 (hC5L2), as well as the C3a receptor, human C3aR (hC3aR), was also determined in order to confirm whether complement receptors were expressed in the RPE cells. Messenger RNA levels of proteasome-related genes did not significantly change after C3a, C5a, and H 2 O 2 treatment for 72 hours. However, IFN-c treatment significantly increased mRNA levels of all genes, 4.9-fold for PSMB5 (b5 subunit), 11.9-fold for PSMB8 (b5i subunit), 3.2-fold for PSMA7 (a7 subunit), and 3.0-fold for PSME1 (PA28 subunit) (n ¼ 8, P < 0.05, Fig. 9 ). Expression of both hC5aR and hC3aR was detected in the HRPE, whereas hC5L2 expression was not detected (data not shown).
These results suggest that the complement factor C3a induced changes in overall proteasome activity are not caused by alterations in gene expression.
DISCUSSION
This study shows that in primary cultures of HRPE, C3a leads to decreased proteasome-mediated proteolytic activity, independent of changes in proteasome components at the protein or transcriptional level, while in a mouse model of age-related atrophic degeneration of the RPE, immunoproteasome upregulation was shown by an increased b5i:b5 ratio. Our results support involvement of alterations in proteasome activity in the cascade of pathologic events that result in this disease process.
Interferon gamma had no effect on the total level of proteasomes, but it did cause an increase in proteasome overall and specific activities, increased relative expression of proteasome regulatory complex PA28a, and increased protein and mRNA expression of immunoproteasome subunits. Interferon gamma caused a switch in the predominance of the inducible chymotrypsin-like subunit b5i over its normal counterpart b5. The resulting b5i:b5 ratio increased by 2.27fold when compared with unstimulated HRPE. This resulted in a high b5i:b5 ratio, which is indicative of more immunoproteasomes. These results are in accordance with previous studies, [51] [52] [53] and show that the observed decreased proteasome activity upon stimulation with C3a cannot be explained by similar mechanisms.
Previous studies have shown that b5-driven proteolytic activity is the rate-limiting activity and the primary effector of protein degradation by the proteasome. 39, 40 Specific inhibition of its activity has the most significant consequences for key processes involved in cell survival under stressful conditions. Neuronal cells that over-expressed a mutant b5 subunit where the active site threonine had been mutated to an alanine were significantly hypersensitive to oxidative stress. 54 The aged retina is exposed to high oxygen tension, high metabolic activity, presence of photosensitive pigments, all culminating in generation of reactive oxygen species 55 that periodically lead to an imbalance in the cellular redox homeostasis. Additionally, and in agreement with our results, proteasome function in the retina is known to be affected by ageing, 41 with the b5 chymotrypsin-like activity of the proteasome being most affected. 41 Our results suggest that in addition to ageing mechanisms, inflammatory mediators such as IFN-c and potentially complement over activation may cause alterations in UPP activity, which may render RPE less tolerant to oxidative stress due to impairment in the clearance of oxidatively damaged proteins.
Decreased overall proteasome activity in the RPE may indirectly contribute to the development of age-related maculopathy. A recent study showed that experimental druginduced proteasome inhibition in the ARPE-19 cell line, a human retinal pigment epithelial cell line with differentiated properties, leads to accumulation of hypoxia-inducible factor 1alpha and diminished activation of the nuclear factor kappalight-chain-enhancer of activated B cells pathway (NF-jB). This led in turn to enhanced expression and secretion of proangiogenic factors such as VEGF and angiopoietin-2 together with an attenuated expression of monocyte chemotactic protein-1. 56 Pathologic angiogenesis due to upregulation of VEGF is one of the most important causes of visual deterioration in AMD. 57 Furthermore, C3a-driven reduced proteasome activity in the RPE could lead to an abnormal regulation of key signaling pathways. For instance, the UPP plays a crucial role in the regulation of pathways that respond to light damage 58, 59 and to melatonin production. 60 Hence, complement-driven proteasome inhibition could impact the circadian cycles of melatonin production and the subsistence of the retina to light-induced damage.
Proteasome inhibition has been shown to increase lipofuscin accumulation and in turn, lipofuscin inhibits the proteasome system due to proteasomal binding to the lipofuscin surface motifs. 61 Lipofuscin, a highly oxidized aggregate, consists of covalently cross-linked proteins, lipids, and sugar residues and is one of the major lifespan-limiting factors in post mitotic ageing cells. 61 Lipofuscin accumulation in the RPE has been reported in ageing and has been implied in many ocular disorders such as AMD, autosomal-recessive Stargardt macular degeneration, and Best's vitelliform macular dystrophy. Potential noxious effects of lipofuscin include photochemical blue light damage, inhibition of lysosomal digestion and proteins, detergent-like disruption of membranes, RPE apoptosis, and DNA damage. Lipofuscinogenesis translates in increased autofluorescence of the retinal fundus. However, it is still unclear whether proteasome inhibition would have the same effects in the RPE because unlike in many cell types in which lipofuscin originates internally (autophagy), lipofuscin derives primarily from phagocytosed photoreceptor outer segments in RPE. 55, [62] [63] [64] [65] [66] [67] [68] Nonetheless, a C3a-induced decrease in overall proteasome activity may contribute to lipofuscinogenesis in age-related maculopathy and AMD.
Besides our studies in in vitro HRPE models, we also studied proteasome function in a mouse model for age-related atrophic degeneration of the RPE. Ambati et al. observed developing features of age-related maculopathy and AMD such as accumulation of lipofuscin, drusen beneath the RPE, photoreceptor atrophy, and choroidal neovascularization. 69 Deposition of complement C3 and C5 intermediates within the RPE and the choroid apparently precedes the accumulation of lipofuscin and deposits in Bruch's membrane. This chain of events is supposedly similar to the processes occurring in human eyes affected by AMD. Complement activation was not present in age-matched wild-type mice. 69 The use of CCL2 À/À mice as a mouse model for AMD has been disputed in recent years. Studies have shown that dysfunction of the chemokine ligandreceptor pair CCL2-CCR2 may lead to deregulated retinal parainflammation mechanisms and retinal lesion development with aging, eventually leading to the development of dry AMD-like lesions in these mice. 69, 70 Other studies, however, have failed to show retinal lesions in these mice. Luhmann et al. reported increased subretinal macrophage accumulation, but no retinal degeneration in aged CCL2 À/À mice. 71 Vessey et al. showed inner retinal (amacrine cell) dysfunction in 9-month-old CCL2/ CX3CR1 GFP/GFP mice. 72 In a recent publication, Chen et al. confirmed results of previous studies in which deficiency of CCL2 led to an identifiable dry AMD-like phenotype. Lesions appeared in these age-dependent CCL2 À/À CX3CR1 GFP/GFP mice not expressing the rd8 mutation, characterized by localized RPE and photoreceptor atrophy similarly to the human geographic atrophy dry type of AMD. 70 In line with these FIGURE 10. Inflammation model of macular degeneration. 6 Age-related macular degeneration may be triggered by one or more environmental risk factors coupled with a genetic susceptibility profile conferred by variants in the CFH, CFB/C2, and/or C3 gene triad. Late in life, such features culminate in the development of pathologic changes in the RPE-choroid complex, which in turn generate a chronic, local inflammatory response characterized by complement over activation, and inflammatory-mediated events. According to our results, release of anaphylatoxin C3a, a complement activation fragment, together with age-related changes, triggers decreased proteasome overall activity. Collectively, complement activation, inflammation-mediated events, and possibly proteasome dysfunction result in the photoreceptor degeneration and the loss of central vision that defines the clinical entity of AMD. results, we performed experiments with CCL2 À/À mice in order to establish an indirect link between age, complement activation, and age-related atrophic degeneration of the RPE. Retinas of CCL2 À/À mice and age-matched wild-type mice were stained for b5 and b5i proteasome subunits. Retinas of CCL2 À/À mice showed an increased b5i:b5 ratio. This was related to a higher content of b5i in the RPE of the knockout mouse model when compared with the age-matched control. The increase in the b5i:b5 ratio observed in CCL2 À/À mice could be one of the rescue mechanisms against retinal toxicity and oxidative stress.
Our study presents some limitations. It remains inconclusive why retinas of CCL2 À/À mice show an increased b5i:b5 ratio. A link with the in vitro experiments with HRPE cells cannot be established. We could not prove, in vitro, that the induction of b5i was specific for complement. The retinas and RPE of CCL2 À/À mice might be exposed to other inflammatory mediators that trigger the observed change in proteasome conformation. Another limitation of our study deals with estimating subunit composition from Western immunoblots in RPE homogenates. Unassembled subunits cannot be distinguished from those that are part of the functional complex. Such mechanism of subunit assembly may be altered by C3a stimulation. Another limitation of our method is the inability to differentiate proteasomes in different cellular compartments. C3a-associated changes in subcellular localization would not be detected using our method. Specific functions, for instance the degradation of misfolded proteins by proteasomes docked outside the endoplasmic reticulum, could be affected should the subcellular content of proteasomes be altered.
In conclusion, our results suggest a link between complement activation and proteasome activity in HRPE cells, which may have implications in the development of age-related maculopathy and AMD (Fig. 10 ). This alteration in UPP activity is not caused by changes in the proteasome composition itself, and probably occurs at a posttranslational level since it is not due to changes in gene expression or changes in the activity of specific proteasome subunits.
